SynderBio's system rapidly eliminates dead, dying cells, and/or non-malignant cells, and dissociates cell aggregates, to deliver a suspension of single, viable cells for analysis or diagnosis. Often there is a mixture of cancer and non-cancerous cells, which is routinely done during cancer diagnosis and is especially vital for Next-Generation Sequencing. Through faster, less labor intensive processing of tumor biopsies and other specimens, SynderBio’s technology benefits researchers, clinicians, pathologists, and patients.

Venture Information
Product Development
Medical Devices
Technology or Science Area: 
Instrument to isolate and evaluate cancer cells.
Single cell analysis instrumentation and cancer diagnostic technologies market
Funding Round: 
Company Information
Michael Henry
Sarah Vigmostad
Mike Cable